Torrent Pharma recalls select Semalix pens after Dr. Reddy's flag
Voluntary, precautionary recall of select batches of Semalix injection pens. No patient safety risk, other semaglutide products unaffected. Event is immaterial for the large-cap pharma.
— 5 earlier stories on Torrent Pharmaceuticals Ltd. →What's new
- Torrent voluntarily recalls select Semalix injection pen batches.
- Recall initiated after Dr. Reddy's technical evaluation notification.
- Only 2 mg and 4 mg presentations affected; patient safety not at risk.
- All other semaglutide products (oral, 8 mg injection) remain unaffected.
Why this matters
For a ₹1,52,849-cr pharma with quarterly sales of ₹4,197 cr, this recall is a routine, minor event. It does not signal quality issues or impact earnings. Semalix is just one product in a broad semaglutide portfolio. Investors should view this as supply-chain vigilance, not a red flag.
What we're watching
- Whether the recall expands to additional batches.
- Any regulatory feedback from CDSCO or FDA.
- Torrent's response to Dr. Reddy's technical evaluation.
The full read
Torrent Pharmaceuticals is recalling select batches of its Semalix injection disposable pens after its contract manufacturer, Dr. Reddy's Laboratories, flagged a technical concern. The recall is voluntary and precautionary: Torrent stresses no patient is at risk. The affected batches cover only 2 mg and 4 mg presentations. All other semaglutide products (the oral tablet and the 8 mg injection) remain on the market. With a market cap of ₹1,52,849 crore and quarterly sales of ₹4,197 crore, an isolated batch recall of a single product is not financially significant. Torrent recently guided to single-digit US growth, but this recall does not change that trajectory. It is a routine supply-chain event, not a red flag.
Questions answered
- Why is Torrent recalling Semalix pens?
- Dr. Reddy's, the contract manufacturer, issued a product recall notification for a technical evaluation. Torrent is voluntarily recalling select batches as a precaution.
- Which batches are affected?
- The recall covers select batches of Semalix injection disposable pens in 2 mg and 4 mg presentations. The 8 mg injection and oral tablet are not affected.
- Is patient safety at risk?
- No. Torrent states there is no risk to patients already on treatment. The recall is precautionary.
- How significant is this recall for Torrent's finances?
- Immature. With a market cap of ₹1,52,849 crore and quarterly sales of ₹4,197 crore, a voluntary recall of select batches of one product is immaterial.
- What other semaglutide products does Torrent sell?
- Torrent markets an oral tablet and an 8 mg injection. Both remain unaffected. Semalix is one of several semaglutide SKUs.
- Has Torrent had similar recalls before?
- The filing does not mention prior recalls. This appears to be an isolated event linked to the manufacturer's technical evaluation.
Torrent Pharmaceuticals Ltd.
Latest quarter · Mar 2026
Strength & growth
Story so far
All notes on TORNTPHARM →- 9 Jul 2026 · 5:35 PM IST Torrent Pharma recalls select Semalix pens after Dr. Reddy's flag
- 44d ago Torrent Pharmaceuticals files transcript for May earnings call
- 49d ago Torrent Pharma walks back US growth targets to single digits
- 49d ago Torrent Pharmaceuticals FY26 results confirm revenue growth of 21%
- 49d ago Torrent Pharmaceuticals eyes ₹5,000 cr QIP following JB Pharma buy